Factor XI inhibitors in patients with cardiovascular disease and a high risk of bleeding: a cautionary tale

B. Gigante; H.T. Cate

doi:10.1038/s41569-023-00872-4

Factor XI inhibitors in patients with cardiovascular disease and a high risk of bleeding: a cautionary tale

B. Gigante, H.T. Cate^*

^*Corresponding author for this work

Research output: Contribution to journal › Editorial › Academic › peer-review

Abstract

Factor XIa inhibitors are being tested in clinical trials, with the assumption that these agents are as effective as direct oral anticoagulants but cause fewer bleeding events. Findings from phase II trials of direct inhibitors of factor XIa for the prevention of first-ever and recurrent ischaemic stroke or recurrent major coronary artery events suggest fewer bleeding events but with uncertainty about efficacy.

Original language	English
Pages (from-to)	511-512
Number of pages	2
Journal	Nature Reviews Cardiology
Volume	20
Issue number	8
Early online date	1 Apr 2023
DOIs	https://doi.org/10.1038/s41569-023-00872-4
Publication status	Published - Aug 2023

Access to Document

10.1038/s41569-023-00872-4

Cite this

@article{5977d006744240a3a9f129f0f60fc7fc,

title = "Factor XI inhibitors in patients with cardiovascular disease and a high risk of bleeding: a cautionary tale",

abstract = "Factor XIa inhibitors are being tested in clinical trials, with the assumption that these agents are as effective as direct oral anticoagulants but cause fewer bleeding events. Findings from phase II trials of direct inhibitors of factor XIa for the prevention of first-ever and recurrent ischaemic stroke or recurrent major coronary artery events suggest fewer bleeding events but with uncertainty about efficacy.",

author = "B. Gigante and H.T. Cate",

note = "Funding Information: H.t.C. has received consultancy fees from Aleveron, AstraZeneca, Galapagos and Novostia and research funding from Bayer; all revenues are deposited at the CARIM Institute and labelled for research. H.t.C. is stockholder of Coagulation Profile, a spinoff diagnostic company of Maastricht University. B.G. declares no competing interests. ",

year = "2023",

month = aug,

doi = "10.1038/s41569-023-00872-4",

language = "English",

volume = "20",

pages = "511--512",

journal = "Nature Reviews Cardiology",

issn = "1759-5002",

publisher = "Nature Publishing Group",

number = "8",

}

TY - JOUR

T1 - Factor XI inhibitors in patients with cardiovascular disease and a high risk of bleeding: a cautionary tale

AU - Gigante, B.

AU - Cate, H.T.

N1 - Funding Information: H.t.C. has received consultancy fees from Aleveron, AstraZeneca, Galapagos and Novostia and research funding from Bayer; all revenues are deposited at the CARIM Institute and labelled for research. H.t.C. is stockholder of Coagulation Profile, a spinoff diagnostic company of Maastricht University. B.G. declares no competing interests.

PY - 2023/8

Y1 - 2023/8

N2 - Factor XIa inhibitors are being tested in clinical trials, with the assumption that these agents are as effective as direct oral anticoagulants but cause fewer bleeding events. Findings from phase II trials of direct inhibitors of factor XIa for the prevention of first-ever and recurrent ischaemic stroke or recurrent major coronary artery events suggest fewer bleeding events but with uncertainty about efficacy.

AB - Factor XIa inhibitors are being tested in clinical trials, with the assumption that these agents are as effective as direct oral anticoagulants but cause fewer bleeding events. Findings from phase II trials of direct inhibitors of factor XIa for the prevention of first-ever and recurrent ischaemic stroke or recurrent major coronary artery events suggest fewer bleeding events but with uncertainty about efficacy.

U2 - 10.1038/s41569-023-00872-4

DO - 10.1038/s41569-023-00872-4

M3 - Editorial

C2 - 37020061

SN - 1759-5002

VL - 20

SP - 511

EP - 512

JO - Nature Reviews Cardiology

JF - Nature Reviews Cardiology

IS - 8

ER -